In this multicentre, randomized, double-blind, controlled, parallel-group trial, 103 patients with type 2 diabetes mellitus and metabolic syndrome were randomized to receive one of two thiazolidinediones -pioglitazone or rosiglitazone -in combination with 1500 mg/day of metformin, increasing up to 3000 mg/day, for 12 months. Anthropometric, metabolic, coagulation and fibrinolysis parameters were assessed at baseline and after 3, 6, 9 and 12 months. Significant decreases in glycosylated haemoglobin, fasting plasma glucose and post-prandial plasma glucose levels were seen after 9 and 12 months in both groups, and significant decreases in fasting plasma insulin and post-prandial plasma insulin levels were seen after 12 months in both groups. In both groups, improvement in the homeostasis model assessment index compared with baseline was obtained only after 12 months. Plasminogen activator inhibitor-1 levels were significantly lower in both groups after 12 months compared with baseline values. In patients with type 2 diabetes mellitus and metabolic syndrome, the combination of metformin plus thiazolidinediones improved glycaemic control and produced a slight but significant reduction in plasminogen activator inhibitor-1 levels.
Introduction
It is well known that diabetes changes the thrombohaemorrhagic balance that exists in healthy flowing blood. This change predisposes the diabetic patient to various thromboembolic conditions, leading to G Derosa, A D'Angelo, PD Ragonesi et al. Effects of rosiglitazone and pioglitazone plus metformin on prothrombotic state increased mortality and morbidity. 1 In various studies, type 2 diabetes mellitus has been shown to be a risk factor for thromboembolic stroke, independent of age, 2 and a strong predictor of venous thromboembolism. 3 Many hypotheses have been proposed to explain the prothrombotic condition of diabetic patients. 4 A main factor could be the increased dietary glycaemic load due to the replacement of fats with carbohydrates or the increased intake of rapidly absorbed carbohydrates (those with a high glycaemic index) creating a selfperpetuating state of insulin resistance, which is known to be associated with greater thrombotic risk. 5 In the context of insulin resistance, insulin has reduced effects on the phosphatidylinositol-3 kinase pathway, whereas mitogen-activated protein kinase activity is maintained. The result is an exaggeration of the mitogenic actions of insulin, leading to vascular smooth muscle proliferation and an elevated level of plasminogen activator inhibitor-1 (PAI-1), 6 the major inhibitor of endogenous thrombolysis, thereby promoting thrombosis. 7 Other factors that may be involved in the thrombophilic status associated with diabetes include increased plasma levels of coagulation factors XII, XI and VIII, 8 platelet hypersensitivity to collagen 9 and an increased circulating pool of tissue factor. 10 Some anti-hyperglycaemic treatments have been demonstrated to reduce blood hypercoagulability in diabetic patients. In particular, metformin, a biguanide, is able to decrease the plasma level of PAI-1 and clotting factor VII. 11 Thiazolidinediones have also been shown to have some beneficial effects on the prothrombotic state of diabetic patients. 12 No direct comparison data are currently available concerning the combined effects of metformin and thiazolidinediones. The aim of this study was to evaluate the differential effects on coagulation and fibrinolysis parameters of the two commercially available thiazolidinediones, pioglitazone and rosiglitazone, combined with metformin in patients with type 2 diabetes mellitus plus metabolic syndrome. The study protocol was approved at each site by an institutional review board and was conducted in accordance with the Declaration of Helsinki and its amendments.
Patients and methods

STUDY DESIGN
PATIENTS
Eligible for inclusion in the study were Caucasian patients aged ≥ 18 years with type 2 diabetes mellitus according to the American Diabetes Association (ADA) criteria 13 with a duration ≥ 6 months and who had poor glycaemic control (glycosylated haemoglobin [HbA 1c ] level > 7.5%) or had experienced adverse effects with diet and metformin given at up to the maximum tolerated dose. All patients also had metabolic syndrome according to the National Cholesterol Education Program Adult Treatment Panel III classification, 14 and presented with triglyceridaemia (triglyceride ≥ 150 mg/dl) 14 and hypertension according to the World Health Organization criteria 15 (systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 85 mmHg). All patients had a fasting C-peptide level > 1.0 ng/ml and G Derosa, A D'Angelo, PD Ragonesi et al.
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were overweight (body mass index [BMI] 25.0 -28.1 kg/m 2 ). 16 Suitable patients were identified from a review of case notes and/or computerized clinic registers and were contacted by the investigators in person or by telephone.
Patients were excluded if they had a history of ketoacidosis or had unstable or rapidly progressive diabetic retinopathy, nephropathy or neuropathy, impaired hepatic function (defined as plasma aminotransferase and/or γ-glutamyltransferase levels higher than the upper limit of normal for age and sex), impaired renal function (defined as a serum creatinine level higher than the upper limit of normal for age and sex), or severe anaemia. Patients with serious cardiovascular disease (such as New York Heart Association class I -IV congestive heart failure or a history of myocardial infarction or stroke) or cerebrovascular conditions within 6 months before study enrolment were also excluded. Women who were pregnant or breastfeeding or of childbearing age and not taking adequate contraceptive precautions were also excluded. All study participants provided written informed consent.
TREATMENT
All patients received metformin, beginning with a dose of 1500 mg/day and increasing if necessary to 3000 mg/day, self-administered for 12 months. The dose that was given depended on the tolerance and glycaemic control of the individual patient.
Patients were randomized (using envelopes containing randomization codes prepared by a statistician) to receive 15 mg pioglitazone or 4 mg rosiglitazone once daily, self-administered each day before lunch for 12 months. A copy of the randomization code was provided only to the person responsible for performing the statistical analysis. The code was only broken after completion of the study, but could have been broken for individual patients in cases of emergency, such as hospitalization or the occurrence of a suspected serious adverse event.
Pioglitazone and rosiglitazone were supplied as identical opaque white capsules in coded bottles to ensure the double-blind status of the study. Participants were given a bottle containing a 100-day supply of study medication and were instructed to take their first dose on the following day. A bottle containing the study medication for the next treatment period was given to participants at the 3-monthly follow-up visits. At the same time, all unused medication was retrieved for inventory. All medications were provided free of charge.
DIET AND EXERCISE
All participants were weighed on joining the study. They then began a controlled-energy diet (~600 kcal daily deficit), based on ADA recommendations, 17 that contained 50% of calories from carbohydrates, 30% from fat (6% saturated) and 20% from proteins, with a maximum cholesterol content of 300 mg/day and 35 g/day of fibre. Standard dietary advice and follow-up were provided by a dietician and/or a specialist physician. Instructions were given on the recording of dietary intake as part of a behaviour modification programme. Beginning at 1 month, these food diaries were used as the basis for counselling. Behaviour modification sessions on weight-loss strategies were given to individual patients by specialist physicians at baseline, at 1 and 6 months and at the end of the study (12 months), and the information contained in the food diaries was used to modify the diet to ensure the correct proportions of the different nutrients. Dieticians provided advice to all patients at baseline and after G Derosa, A D'Angelo, PD Ragonesi et al.
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3, 6, 9 and 12 months, independent of the diet information they had given, to verify that they were following the correct lifestyle (i.e. appropriate diet and physical activity).
Patients were also encouraged to increase their physical activity by walking briskly or riding a stationary bicycle for 20 -30 min three to five times per week. Changes in physical activity were not assessed.
ASSESSMENT OF EFFICACY, TOLERABILITY AND COMPLIANCE
Before starting the study, all patients underwent an initial screening that included a medical history, physical examination, measurement of vital signs, a 12-lead electrocardiogram, measurement of height and body weight, assessment of glycaemic control (HbA 1c , fasting and post-prandial plasma glucose levels [FPG and PPG, respectively], fasting and post-prandial plasma insulin levels [FPI and PPI, respectively]), measurement of PAI-1, tissue plasminogen activator (t-PA), fibrinogen, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels.
The BMI was calculated from body weight and height. An estimate of insulin resistance was calculated using the homeostasis model assessment (HOMA) index from the following formula: 18 insulin resistance = FPI (µU/ml) × FPG (mmol/l)/22.5
The BMI, HbA 1c , FPG, PPG, FPI, PPI, HOMA index, PAI-1, t-PA, fibrinogen, AST and ALT were assessed again after 3, 6, 9 and 12 months of treatment.
All plasma variables were determined after a 12-h overnight fast, the venous blood samples being drawn between 08.00 and 09.00, except for PPG and PPI, which were determined 2 h after lunch. After the addition of 1 mg/ml disodium ethylene diamine tetra-acetic acid, samples were centrifuged at 3000 g for 15 min at 4°C, frozen and stored at -80°C for ≤ 3 months. All plasma measurements were performed in a central laboratory.
The HbA 1c level was measured using high-performance liquid chromatography (Diamat™, Bio-Rad Laboratories, Inc., Hercules, California, USA; normal value 4.2 -6.2%, intra-and inter-assay coefficients of variation < 2%). 19 Plasma glucose was assayed using a glucose oxidase method (GOD/PAP, Roche Diagnostics, Mannheim, Germany; intra-and inter-assay coefficients of variation < 2%). 20 Plasma insulin was assayed with the Phadiaseph insulin radioimmunoassay (Pharmacia, Uppsala, Sweden) using a second antibody to separate the free and antibody-bound 125 I-insulin (intra-and inter-assay coefficients of variation 4.6 and 7.3%, respectively). 21 Levels of PAI-1 were assayed with a commercial two-stage indirect enzymatic assay (Spectrolyse ® , Biopool AB, Umea, Sweden; intra-and inter-assay coefficients of variation were both 5.9%). 22 Fibrinogen was determined according to Clauss 23 (intraassay coefficient of variation < 5%). Levels of t-PA were measured using a commercially available enzyme-linked immunosorbent assay kit (Spectrolyse ® ; intra-and inter-assay coefficients of variation 7.0 and 10.4%, respectively). 24 AST 25 and ALT 26 were measured using kinetic UV-optimized methods of the IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) (SGM Italia, Rome, Italy). The intra-and inter-assay coefficients of variation were 2.42 and 2.29%, respectively, for AST and 2.07% and 2.24%, respectively, for ALT.
Treatment tolerability was assessed at each study visit by interviewing the patients and comparing clinical and laboratory values with baseline levels. Medication compliance was assessed by counting the number of pills returned at the clinic visits.
STATISTICAL ANALYSIS
Changes in BMI, HbA 1c , PAI-1, t-PA and fibrinogen were the primary efficacy variables. FPG, PPG and the HOMA index were also used to assess efficacy; a HOMA index ≥ 2.5 was considered to indicate insulin resistance.
An intention-to-treat analysis was conducted in all patients who had received at least one dose of study medication and who had subsequently been assessed for efficacy. Patients were included in the tolerability analysis if they had received at least one dose of trial medication after randomization and had subsequently been assessed for tolerability. The null hypothesis that the expected mean PAI-1, t-PA and fibrinogen change from baseline to the end of 12 months of double-blind treatment would not differ significantly between pioglitazone and rosiglitazone treatments was tested using analysis of variance for repeated measures and analysis of covariance (ANCOVA) models. 27 Similar analyses were applied to the other variables. The statistical significance of the independent effects of the treatments on the other variables was determined using ANCOVA. A one-sample t-test was used to compare values obtained before and after treatment administration; two-sample t-tests were used for between-group comparisons. The Bonferroni correction for multiple comparisons was used. Statistical analysis of data was performed using the SPSS ® software version 11.0 (SPSS Inc., Chicago, Illinois, USA). Data are presented as mean ± SD. For all statistical analyses, a P-value < 0.05 was considered to be statistically significant.
Results
PATIENTS
A total of 103 patients were enrolled in the trial. Of these, 96 patients completed the study; 48 (50%) received metformin plus pioglitazone and 48 (50%) received metformin plus rosiglitazone. Seven patients (three males and four females) did not complete the study; the reasons for premature withdrawal included protocol violation, loss to follow-up and non-compliance.
The characteristics of the patient population at study entry, shown in Table 1 , were similar in the two treatment groups.
EFFICACY
Body mass index
No changes in BMI were observed compared with baseline in either group, and there was no difference in BMI values between the two groups (Tables 2 and 3 ).
Glycaemic control
The mean dose of metformin, which was titrated according to tolerance and glycaemic control, was 2250 ± 750 mg/day.
No change in HbA 1c was observed after 3 and 6 months in either group, whereas a significant decrease compared with baseline was seen after 9 months (P < 0.05) and 12 months (P < 0.01) in both groups (Tables 2 and 3 ). No significant variations in FPG and PPG levels were present after 3 and 6 months in either group, but a significant decrease compared with baseline was observed in both groups after 9 months (P < 0.05) and 12 months (P < 0.01) (Tables 2  and 3 ). FPI and PPI did not show any significant change after 3, 6 and 9 months, but a significant decrease compared with baseline was observed at 12 months (P < 0.05) in both groups (Tables 2 and 3) . A significant improvement (P < 0.05) in the HOMA index compared with baseline was only seen after 12 months in both groups (Tables 2 and 3 ). 
TABLE 1: Baseline data for patients with type 2 diabetes mellitus plus metabolic syndrome treated with metformin plus pioglitazone or metformin plus rosiglitazone
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Coagulation and fibrinolysis effects
No changes in PAI-1 levels were observed in either group after 3, 6 and 9 months, whereas significant reductions (P < 0.05) in PAI-1 compared with baseline were seen in both groups after 12 months (Tables 2 and 3 ; Fig. 1 ). No significant changes in t-PA or fibrinogen were seen during the study in either group (Tables 2 and 3 ).
TOLERABILITY
Of the 96 patients who completed the study, 8.3% (four out of 48) of the patients in the pioglitazone group and 10.4% (five out of 48) of the patients in rosiglitazone group had side-effects; this difference was not significant. In the pioglitazone group, two patients had AST and ALT values that increased to 1.5 times the upper limit of normal (< 40 U/l), but these values regressed after 15 days and returned to within the normal limits; in addition, two patients reported transient headache (for 7 days from the start of the therapy). In the rosiglitazone group, three patients had AST and ALT values that increased to twice the upper limit 
G Derosa, A D'Angelo, PD Ragonesi et al. Effects of rosiglitazone and pioglitazone plus metformin on prothrombotic state
of normal (< 40 U/l), but these values regressed after 15 days and returned to within the normal limit; in addition, two patients reported transient headache (for 3 days from the start of the therapy) and one of these patients also reported transient flatulence, which began 1 day after the start of the therapy and lasted for 4 days.
Overall, there were no statistically significant changes in aminotransferase levels; AST and ALT values were 22 ± 6 U/l and 24 ± 8 U/l, respectively, at baseline and 25 ± 8 U/l and 26 ± 9 U/l, respectively, at 12 months in the pioglitazone group, and 23 ± 8 U/l and 25 ± 9 U/l, respectively, at baseline and 25 ± 9 U/l and 27 ± 10 U/l, respectively, at 12 months in the rosiglitazone group.
Discussion
Type 2 diabetes mellitus is a progressive disorder. Although oral monotherapy is often initially successful, it is associated with a high secondary failure rate that contributes to the development of long-term diabetes complications resulting from persistent hyperglycaemia. 28 For patients not taking insulin, accumulating evidence suggests that combination therapy using oral anti-diabetic agents with different mechanisms of action may be highly effective in achieving and maintaining target blood glucose levels. 29 The use of combinations of oral agents may delay the need for insulin while maintaining glycaemic control, thus making aggressive oral treatment more acceptable for many patients. 30 Metformin is a biguanide anti-hyperglycaemic drug that has been used for the treatment of type 2 diabetes mellitus for over 40 years. Its main mechanism of action is to counteract peripheral insulin resistance. 31 Moreover, metformin is the only antihyperglycaemic drug that has been shown to have relevant positive effects on hard clinical outcomes. It reduced the number of vascular events by approximately 40% in a large retrospective Canadian study carried out on more than 12 000 patients, 32 it significantly reduced various diabetes-related endpoints in the United Kingdom Prospective Diabetes Study, 33 and it decreased the incidence of diabetes by 31% in the large Diabetes Prevention Program study. 34 Biochemically, metformin reduces triglyceride, PAI-1, factor VII and C-reactive protein levels. 35 In addition, recent studies have indicated that metformin has direct effects on fibrin structure and function, and stabilizes platelets, two important components of arterial thrombus. 11 Thiazolidinediones are a newer class of oral hypoglycaemic agents. Their hypoglycaemic effect is related to their ability to increase insulin sensitivity and, consequently, increase peripheral glucose utilization. Although the exact mechanism of action is not completely understood, the most widely accepted hypothesis is that their effect on insulin sensitivity is related to their well-known ability to bind and activate the nuclear peroxisomal proliferatoractivated receptor-γ. 36 To the best of our knowledge, this is the first randomized, double-blind clinical trial to compare the effects of metformin plus pioglitazone and metformin plus rosiglitazone on various parameters of coagulation and fibrinolysis, and thus on atherothrombotic risk, in patients with type 2 diabetes mellitus plus metabolic syndrome.
The optimal effect of thiazolidinediones on glycaemic control in diabetic subjects is already known 37, 38 and was further confirmed by the present study: the combination of metformin with pioglitazone or metformin with rosiglitazone significantly improved glycaemic control at 12 months, with improvements, respectively, of 17.1% and G Derosa, A D'Angelo, PD Ragonesi et al.
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16.0% in the plasma level of HbA 1c (P < 0.01, respectively), 13.0% and 11.0% in FPG (P < 0.01, respectively), 16.1% and 12.0% in PPG (P < 0.01, respectively) and 16.7% and 16.1% in PPI (P < 0.05, respectively). There were no significant differences between the two treatment groups. As seen in previous studies, 37, 38 only pioglitazone appeared to have a positive effect on plasma lipid levels (total cholesterol decreased by 9.8%, highdensity lipoprotein cholesterol increased by 9.1% and triglyceride decreased by 25.0%).
We have previously reported that both pioglitazone and rosiglitazone when combined with glimepiride produced a statistically significant decrease (of 22%) in PAI-1 plasma levels, with no difference between the two groups. 12 In the present study, we observed that both the group receiving pioglitazone plus metformin and the group receiving rosiglitazone plus metformin experienced a significant (P < 0.05) reduction in the plasma level of PAI-1 (14.9% and 15.4%, respectively) after 12 months, again with no significant difference between the two groups. The positive effect of thiazolidinediones on plasma levels of PAI-1 is in agreement with the results of a pre-clinical study carried out by Harte et al. 39 on human abdominal subcutaneous adipocytes and with those of our previous report. 12 In addition, metformin could have contributed to the observed effect. 35 No significant changes were seen in t-PA or fibrinogen levels in either the pioglitazone or the rosiglitazone group.
In conclusion, both of the drug combinations tested have been shown to be safe and effective with regard to glycaemic control and both improve plasma levels of PAI-1 in patients with type 2 diabetes mellitus plus metabolic syndrome. This study did not include a comparison with placebo or metformin alone; consequently, it is not possible to conclude whether these effects are produced by metformin, the thiazolidinediones, or the combination of the two drugs. Further research on larger population samples is needed to evaluate whether the observed results will be reflected in a long-term reduction in the incidence of cardiovascular disease.
